Eli Lilly's Q1 numbers showed strong revenue and earnings growth, driven by its GLP-1 offerings. The company's 2025 outlook disappointed investors, however, leading to the decline. The stock ...

Eli Lilly recently experienced a slight decline in share price of 1.38% over the last month. This period coincided with several key events for the company, such as earnings that showed improved ...

Michael Nagle / Bloomberg via Getty Images Shares of Eli Lilly (LLY) fell sharply Thursday morning after the pharmaceutical giant's lowered profit projections outweighed first-quarter results that ...

The head of drugmaker Eli Lilly, which sells the popular weight-loss drug Zepbound, urged the Trump administration to ease up on its tariff rollout because it could hurt Lilly’s business and the ...

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported weak first quarter 2025 results which included an EPS miss due to ...

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Goldman Sachs cuts Eli Lilly's price target to $883, citing PBM-related uncertainty after CVS dropped Zepbound. BofA keeps $1,000 price target, saying Zepbound remains superior and CVS move is not ...

Being first to market with a drug can be crucial. Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved in its home country ...

Eli Lilly & Co.’s stock soared 14% Thursday, to put it on track for its biggest one-day gain in about 25 years, after the drugmaker reported positive results from a late-stage trial of a GLP-1 ...

Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options ... Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing ...

In JPMorgan's view, CVS's move "will likely impact only a small portion of Eli Lilly's Zepbound business ... maybe cutting prices through a partner like Novo is doing, or maybe simply cutting ...

Shares of Eli Lilly (NYSE: LLY) sank after the drugmaker lowered its full-year profit outlook, and a potential headwind to pricing and access to its drug Zepbound emerged. However, the guidance ...